Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7214506 | BAUSCH | Method for treating onychomycosis |
Feb, 2026
(1 year, 10 months from now) | |
US10828369 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(3 years from now) | |
US11872218 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(3 years from now) | |
US9566272 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(3 years from now) | |
US9877955 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(3 years from now) | |
US10512640 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(3 years from now) | |
US11213519 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(3 years from now) | |
US8039494 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(6 years from now) | |
US9861698 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(6 years from now) | |
US10105444 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(6 years from now) | |
US8486978 | BAUSCH | Compositions and methods for treating diseases of the nail |
Oct, 2030
(6 years from now) | |
US9302009 | BAUSCH | Compositions and methods for treating diseases of the nail |
Oct, 2030
(6 years from now) | |
US11654139 | BAUSCH | Anti-infective methods, compositions, and devices |
Oct, 2034
(10 years from now) | |
US9662394 | BAUSCH | Stabilized efinaconazole compositions |
Oct, 2034
(10 years from now) | |
US10342875 | BAUSCH | Stabilized efinaconazole compositions |
Oct, 2034
(10 years from now) | |
US10864274 | BAUSCH | Stabilized efinaconazole formulations |
Oct, 2034
(10 years from now) | |
US10828293 | BAUSCH | Anti-infective methods, compositions, and devices |
Oct, 2034
(10 years from now) | |
US10478601 | BAUSCH | Applicator |
Apr, 2035
(11 years from now) |
Jublia is owned by Bausch.
Jublia contains Efinaconazole.
Jublia has a total of 18 drug patents out of which 0 drug patents have expired.
Jublia was authorised for market use on 06 June, 2014.
Jublia is available in solution;topical dosage forms.
Jublia can be used as antimycotic uses, specifically treatment of onychomycosis, topical treatment of onychomycosis of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes, topical treatment of tinea unguium by using an applicator for applying a solution for treating tinea unguium to an affected part of a patient, antimycotic uses, specifically treatment of onychomycosis; topical treatment of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes.
The generics of Jublia are possible to be released after 25 April, 2035.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Apr 27, 2023 |
Drugs and Companies using EFINACONAZOLE ingredient
Market Authorisation Date: 06 June, 2014
Treatment: Antimycotic uses, specifically treatment of onychomycosis; Topical treatment of onychomycosis of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes; Topical treatment of the toe...
Dosage: SOLUTION;TOPICAL